ALEXANDRIA, VA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC, founded in 1965, is a major nonprofit in the Diseases & Disorders sector that reported $174.3M in total revenue in fiscal year 2023. Revenue grew 19% year-over-year, indicating healthy expansion. Expenses of $155.5M left a modest 11% surplus.
:ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE.
SEAN KHOZIN RECEIVED SEVERANCE IN THE AMOUNT OF $395,769 IN 2023.
:QUALITY OF CARE INITIATIVES - CANCERLINQ, QUALITY MEASURES, GUIDELINES AND QOPI:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL...
:QUALITY OF CARE INITIATIVES - CANCERLINQ, QUALITY MEASURES, GUIDELINES AND QOPI:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 263 PRATICES PARTICAPTED IN 2023.QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS, THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. RECENT PARTICPANTS HAVE INCLUDED, BY INTENTIONAL RECRUITMENT, PRACTICES SERVING URBAN AND RURAL UNDERSERVED POPULATIONS ADRESSING HEALTH DISPARITY. 290 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2023.GUIDELINES:A CRITICAL COMPONENT OF THE SOCIETY'S QUALITY EFFORTS, THE ASCO GUIDELINES PROGRAM ACTIVELY ENGAGES WITH MORE THAN 1,000 ASCO MEMBER VOLUNTEERS, ON A YEARLY BASIS, TO DEVELOP EVIDENCE AND EXPERT-DRIVEN RECOMMENDATIONS THAT INFORM HIGH-QUALITY AND EQUITABLE CANCER CARE WORLDWIDE. ASCO'S GUIDELINES PROGRAM WHICH INCLUDES TRADITIONAL AS WELL AS LIVING CLINICAL PRACTICE GUIDELINES, UPDATES, AND ORGANIZATIONAL STANDARDS, FOCUSES ON CONTENT AREAS WITH IDENTIFIED KNOWLEDGE GAPS, HIGH UNCERTAINTY, OR UNMET AND PRESSING CLINICAL NEEDS FACING ONCOLOGY CARE TEAMS IN CLINICAL PRACTICE. ASCO'S GUIDELINES RESOURCES ARE DESIGNED TO PROMOTE GUIDELINE-CONCORDANT CANCER CARE AT THE CLINICIAN, CAREGIVER, AND PATIENT LEVEL. FOR PATIENTS AND CAREGIVERS, COMPLEX GUIDELINE INFORMATION IS DISTILLED AND PRESENTED IN A USER-FRIENDLY FORMAT THROUGH ASCO'S CANCER.NET. FOR CLINICIANS, THESE TOOLS ARE OFFERED THROUGH CONCISE PRACTICE-FACING COMPANION ARTICLES, SUMMARY RECOMMENDATION TABLES, ALGORITHMS, PODCASTS, VISUAL ABSTRACTS, AND OTHER RESOURCES THAT ARE ACCESSIBLE THROUGH ASCO JOURNALS, THE ASCO WEBSITE, AND THE ASCO GUIDELINES APP.PUBLISHED AS A REGULAR, AND OFTEN MOST READ, FEATURE IN THE JOURNAL OF CLINICAL ONCOLOGY (JCO) WITH OVER 1.3 MILLION DOWNLOADS IN 2023, GUIDELINES ALSO SERVE AS THE EVIDENCE FOUNDATION FOR ASCO'S MEMBER EDUCATION, PATIENT EDUCATION, POLICY, CARE DELIVERY, AND QUALITY EFFORTS, ALL WITH THE GOAL OF CANCER TREATMENT AND CARE INFORMED BY THE HIGHEST QUALITY EVIDENCE AND EXPERT INTERPRETATION, INTEGRATED INTO GLOBAL PRACTICE AT THE POINT OF PATIENT CARE. ASCO TYPICALLY ENGAGES 30-40 GUIDELINE EXPERT PANELS AT ANY GIVEN TIME AND PUBLISHES BETWEEN 20-25 NEW OR UPDATED GUIDELINES EACH YEAR; WITH A GROWING LIBRARY OF GUIDELINE SUMMARIES THAT HAVE BEEN TRANSLATED INTO SPANISH. TWENTY-THREE GUIDELINE PRODUCTS WERE PUBLISHED IN THE JCO IN 2023, INCLUDING SEVERAL RAPID UPDATES AND MULTIPLE ITERATIONS OF ASCO'S COMPREHENSIVE LIVING GUIDELINE ADDRESSING THE CARE OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER. IN ADDITION, 13 COMPANION ARTICLES PROVIDING GUIDELINE CLINICAL INSIGHTS WERE PUBLISHED IN THE JCO ONCOLOGY PRACTICE.
:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS LEADS ASCO'S RESEARCH EFFORTS, INCLUDING ITS CLINICAL CANCER RESEARCH PROGRAMS. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1)...
:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS LEADS ASCO'S RESEARCH EFFORTS, INCLUDING ITS CLINICAL CANCER RESEARCH PROGRAMS. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY WHICH IS PRECISION MEDICINE BASKET TRIAL INVESTIGATING THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED ALMOST THAN 3,000 PATIENTS SINCE IT OPENED IN 2016 AND CONTINUES TO PUBLISH TRIAL RESULTS IN PEER-REVIEWED CLINICAL CANCER RESEARCH JOURNALS AND PRESENT RESULTS AT CLINICAL CANCER RESEARCH CONFERENCES; (2) ASCO'S COVID-19 REGISTRY WHICH INCLUDES A DATABASE OF OVER 6,000 PATIENTS WITH CANCER AND COVID-19 FROM 2020 TO 2022 AND RESEARCH ON THE DATABASE BY CENTRA STAFF AND MADE AVAILABLE TO EXTERNAL RESEARCHERS (THE REGISTRY CLOSED TO DATA COLLECTION AT THE END OF 2023 ALTHOUGH DATA IS STILL AVAILABLE FOR USE); (3) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (4) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH ASSESSES AND REPORTS ON AND REPORT ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US; (5) ASCO'S WORK IN IMPROVING ACCESS TO CLINICAL TRIALS THROUGH TRAINING FOR SITES AND WORKING TO COMBAT BARRIERS TO ENROLLMENT FOR UNDER-REPRESENTED POPULATIONS OF PATIENTS; AND (6) THE START-UP FOR A NEW CLINICAL RESEARCH STUDY, THE CDK4/6 INHIBITOR DOSING STUDY, WHICH WILL OPEN TO ENROLLMENT IN 2024 AND EVALUATES STANDARD VS. TITRATED DOSING APPROACHES FOR PATIENTS AGE 65 AND OLDER WITH HR+/HER2- METASTATIC BREAST CANCER. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $174,337,293 | $146,139,860 | +0.2% |
| Expenses | $155,488,043 | $144,269,886 | +0.1% |
| Net Income | $18,849,250 | $1,869,974 | +9.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| EVERETT E VOKES MD | CHAIR/PAST PRESIDENT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| ERIC P WINER MD | PRESIDENT/CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| LYNN M SCHUCHTER MD | PRESIDENT-ELECT/PRESIDENT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| ROBIN ZON MD | PRESIDENT-ELECT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| LORI J PIERCE MD | PAST PRESIDENT (PARTIAL YEAR) | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| ELIZABETH A MITTENDORF MD PHD MHC | TREASURER (PARTIAL YEAR) | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| ELIZABETH R PLIMACK MD MS | TREASURER-ELECT/TREASURER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| TAOFEEK K OWONIKOKO MD PHD | TREASURER-ELECT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| FREDRICK CHITE ASIRWA MD MBCHB | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ETHAN M BASCH MD MSC | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| LISA A CAREY MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MARIANA CHAVEZ MACGREGOR MD MSC | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| TARA O HENDERSON MD MPH | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| CAROLYN B HENDRICKS MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| KATHLEEN N MOORE MD MS | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| ANN H PARTRIDGE MD MPH | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| DEBRA PATT MD PHD | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| ENRIQUE SOTO PEREZ DE CELIS MD MSC | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| GLADYS I RODRIGUEZ MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JENNIFER TEMEL MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL A THOMPSON MD PHD | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| KAREN M WINKFIELD MD PHD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| CLIFFORD A HUDIS MD | CEO | 30.00 |
Officer
|
$1,060,801 | $24,750 | $1,085,551 |
| DINA MICHELS ESQ | SECRETARY, EVP & COO | 37.50 |
Officer
|
$685,749 | $42,792 | $728,541 |
| LINDA JENSEN | EVP & CFO | 30.00 |
Officer
|
$477,532 | $42,792 | $520,324 |
| JULIE R GRALOW MD | EVP & CMO | 37.50 |
Key Emp
|
$632,400 | $42,792 | $675,192 |
| NANCY DALY MS MPH | EVP & CONQUER CANCER CEO | 1.00 |
Key Emp
|
$516,637 | $42,677 | $559,314 |
| CARMEN JACKSON | CEO - CLQ | 37.50 |
Key Emp
|
$515,125 | $49,419 | $564,544 |
| CHRISTOPHER MERLAN | EVP & CHIEF DIGITAL OFFICE | 37.50 |
Key Emp
|
$475,728 | $44,731 | $520,459 |
| JAMIE VON ROENN MD MED | VP, EDU., SCIENCE & PROF. | 37.50 |
Key Emp
|
$457,512 | $33,834 | $491,346 |
| AMANDA DAVIS-AITKEN | VICE PRESIDENT, MEETING SV | 37.50 |
Key Emp
|
$338,635 | $33,749 | $372,384 |
| ANGELA COCHRAN | VP, PUBLISHING | 37.50 |
Key Emp
|
$336,979 | $40,401 | $377,380 |
| BARTON LAWYER | VICE PRESIDENT - IT | 37.50 |
Key Emp
|
$303,038 | $47,169 | $350,207 |
| STEPHEN GRUBBS MD | VP, CARE DELIVERY | 37.50 |
Highest
|
$445,051 | $42,606 | $487,657 |
| KRISTEN NEESE | CHIEF MARKETING & COMMUNICATIONS OFFICER | 37.50 |
Highest
|
$363,368 | $44,731 | $408,099 |
| PAULA KING | CHIEF HUMAN RESOURCES OFFICER | 37.50 |
Highest
|
$362,762 | $44,731 | $407,493 |
| DEBORAH KAMIN PHD | VP, POLICY/ADVOCACY | 30.00 |
Highest
|
$356,959 | $42,677 | $399,636 |
| MELISSA TAI | VP, CEIL & GENERAL COUNSEL | 29.50 |
Highest
|
$350,115 | $49,281 | $399,396 |
| SEAN KHOZIN MD | FORMER CLQ CEO | 37.50 |
|
$395,769 | $0 | $395,769 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $174,337,293 | $155,488,043 | $296,538,439 | $18,849,250 |
| 2022 | $146,139,860 | $144,269,886 | $251,452,025 | $1,869,974 |
| 2021 | $107,588,628 | $119,778,637 | $283,820,689 | $-12,190,009 |
| 2020 | $138,374,082 | $134,735,801 | $279,249,289 | $3,638,281 |
| 2019 | $162,711,421 | $148,108,869 | $269,484,782 | $14,602,552 |
| 2018 | $159,884,094 | $145,806,474 | $227,652,015 | $14,077,620 |
Compare AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC with other nonprofits in Virginia and across the country.